SCHEMBL3678093

SCHEMBL3678093

CCP(CC)CC.CCP(CC)CC.[Ni]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10385788 1.00
SCHEMBL10958120 1.00
SCHEMBL5589491 1.00
Hydrochloric Acid SCHEMBL10336831 0.95
Hydrochloric Acid SCHEMBL2124370 0.95
SCHEMBL41401 0.94
SCHEMBL5409330 0.94
SCHEMBL23495442 0.89
SCHEMBL1985723 0.89
SCHEMBL3839574 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017016688-A1 NOVEL CATALYTIC COMPOSITION COMPRISING NICKEL AND A LIGAND OF THE PHOSPHINE COMPLEXED WITH NICKEL TYPE, AND USE THEREOF IN AN OLEFIN OLIGOMERISATION METHOD IFP Energies Nouvelles (FR) 2017-02-02 WO claimed
EP-0091232-B1 BUTENE DIMERIZATION METHOD EXXON RESEARCH AND ENGINEERING COMPANY (US) 1985-07-10 EP claimed
WO-2017016688-A1 NOVEL CATALYTIC COMPOSITION COMPRISING NICKEL AND A LIGAND OF THE PHOSPHINE COMPLEXED WITH NICKEL TYPE, AND USE THEREOF IN AN OLEFIN OLIGOMERISATION METHOD IFP Energies Nouvelles (FR) 2017-02-02 WO disclosed
EP-2838891-A1 AROMATIC RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-02-25 EP disclosed
EP-1731505-B1 ALKOXYPHENYLPROPANOIC ACID DERIVATIVES TAKEDA PHARMACEUTICAL (JP) 2015-01-14 EP disclosed
WO-2013125732-A1 AROMATIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-29 WO disclosed
EP-2611805-A1 FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT Takeda Pharmaceutical Company Limited (JP) 2013-07-10 EP disclosed
EP-2585462-A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2013-05-01 EP disclosed
WO-2012029991-A1 FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-08 WO disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed
US-20100185019-A1 CATALYST COMPOSITION AND PROCESS FOR PRODUCING CROSS-COUPLED COMPOUND USING SAME TOSOH FINECHEM CORPORATION (JP) 2010-07-22 US disclosed
WO-2005063729-A1 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-07-14 WO disclosed
EP-1222190-A1 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS Pfizer Limited (GB) 2002-07-17 EP disclosed
WO-2001027112-A1 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS PFIZER LIMITED (GB) 2001-04-19 WO disclosed
EP-0790993-A1 NONPEPTIDE ENDOTHELIN ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-08-27 EP disclosed
US-5482960-A Nonpeptide endothelin antagonists WARNER-LAMBERT COMPANY (US) 1996-01-09 US disclosed
EP-0175384-B1 CERAMIC MATERIALS WITH INCREASED CRYSTALLINITY FROM SILAZANE POLYMERS DOW CORNING CORPORATION (US) 1989-08-09 EP disclosed
US-4757035-A Heating modified silazane polymer containing crystallinity increasing amount of iron or copper compound DOW CORNING CORPORATION (US) 1988-07-12 US disclosed
EP-0175384-A2 Ceramic materials with increased crystallinity from silazane polymers DOW CORNING CORPORATION (US) 1986-03-26 EP disclosed
EP-0052929-A1 Sulfonated group VA ylides and process for preparing same GULF RESEARCH & DEVELOPMENT COMPANY (US) 1982-06-02 EP disclosed